“As Novartis we obviously do research, we are committed to making innovative and potentially resolving therapies available also for patients with chronic myeloproliferative neoplasms but I believe that a company should not only deal with this but above all be at the side of patients and clinicians. So supporting initiatives such as ‘Mielo-Spieghi’ and its lively community is absolutely fundamental because real strength comes from closeness, from being able to share their experiences among patients and this gives them a great opportunity. So supporting activities of this kind is part of our mission of being close to patients“. Like this Luigi BoanoGeneral Manager Novartis Oncology Italia, on the occasion of the presentation of ‘Mielo-Spieghi 2022’, the information campaign on chronic myeloproliferative neoplasms, promoted by Novartis in collaboration with Aipamm and with the patronage of Ail and the MPN Advocates Network.
“Our first goal – added Boano – is to make innovative therapies available to potentially solve oncological pathologies, so the company is oriented, as it has already done in the past, to devote maximum resources and energy to discovering therapies that can definitively improve and, possibly, cure hematological neoplasms and solid tumors “. “We are a company very present and rooted in Italy, Italian centers are involved in the research and development of innovative therapies for these pathologies and this has a positive impact also on the patients themselves”, he concludes.